Back to search results
NCT07646652

Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease

Not Yet Recruiting
Not specifiedAges 40–85Observational
Stanford University
~40 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:LBD Biomarker Education and Disclosure

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in distress scale score as measured by the Impact of Event Scale-Revised
Measured over Baseline, Day 14, Day 30, Day 182

Conditions

Lewy Body Disease

Explore related trials

Dementia associated with Parkinson's DiseaseLewy Body DementiaMild cognitive disorderMild Cognitive Impairment in Parkinson's DiseaseMultiple System AtrophyParkinson DiseaseAlpha-Synuclein

NCT07646652

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Stanford University

    Stanford, Californiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Irina A Skylar-Scott, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Olivia Lu
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to provide 1) written, informed consent or 2) assent if a care partner can provide consent.
Access to a primary care or neurology provider for ongoing care.
1\) willing to undergo skin biopsy or lumbar puncture for alpha-synuclein testing or 2) has access to as-yet undisclosed skin biopsy or lumbar puncture alpha-synuclein testing results.
Undergoing testing for defined reason (e.g., research study)
Mini-Mental State Examination score between 26 and 30 (or MoCA between 25 and 30)
General good health (no diseases expected to interfere with the study)
Referred by a neurologist or movement disorder specialist
Adults with any of the following: symptomatic LBD, mild cognitive impairment with Lewy body (MCI-LB), Parkinson's disease dementia (PDD), MCI in Parkinson's disease (PD-MCI), or criteria for multiple system atrophy (MSA).

Exclusion

Clinician judgment that disclosure poses unacceptable psychological risk.
Concurrent enrollment in a trial with conflicting disclosure protocols.

What this trial measures

  • Change in distress scale score as measured by the Impact of Event Scale-RevisedBaseline, Day 14, Day 30, Day 182

    Distress related to biomarker disclosure will be assessed via the validated Impact of Event Scale-Revised (IES-R, a 22 item self-report measure). Scores range from 0 to 88; higher scores mean greater distress.